nChroma Bio

nChroma Bio

Advancing targeted genetic medicine with safe, precise in vivo delivery, focusing on liver therapies like CRMA-1001 to address chronic hepatitis B and D using epigenetics.

HQ location
Cambridge, United States
Website
nchromabio.com
Launch date
Employees
51-200 people
Enterprise value
$300—450m
https://www.linkedin.com/company/nchroma-bio/
    • Edit
GV
GV
F-Prime
F-Prime
DCVC Bio
DCVC Bio
5AM Ventures
5AM Ventures
Mubadala Capital
Mubadala Capital
Janus Henderson Investors
Janus Henderson Investors
Sofinnova Partners
Sofinnova Partners
Sixth Street
Sixth Street
Omega Funds
Omega Funds
Cormorant Asset Management
Cormorant Asset Management
Newpath Management
Newpath Management
Atlas Venture
Atlas Venture
ARCH Venture Partners
ARCH Venture Partners
Alexandria Venture Investments
Alexandria Venture Investments
Wellington Management
Wellington Management
T. Rowe Price
T. Rowe Price
Wilson Sonsini
Wilson Sonsini
Menlo Ventures
Menlo Ventures
Casdin Capital
Casdin Capital

Related Content

Analytics
Unlock the full power of analytics with a premium account
Track company size and historic growth
Track team composition and strength
Track website visits and app downloads

Investments by nChroma Bio

Edit
Chroma Medicine
Chroma Medicine
Nvelop Therapeutics
Nvelop Therapeutics